Please login to the form below
Sutimlimab
This page shows the latest Sutimlimab news and features for those working in and with pharma, biotech and healthcare.
FDA issues approval for Sanofi’s Enjaymo treatment for patients with CAD
The US FDA has approved Sanofi’s Enjaymo (sutimlimab-jome) for the treatment of adults diagnosed with the rare blood disorder, cold agglutinin disease (CAD).
Latest news
-
Sanofi’s sutimlimab set for filing in rare autoimmune anaemia next year
Sutimlimab – a first-in-class selective inhibitor of complement C1s – has hit the mark in cold agglutinin disease (CAD), a rare, autoimmune form of haemolytic anaemia that causes blood clots, leading ... In the phase 3 CARDINAL study reported at the
-
Sanofi exits R&D pact with Alnylam on rare disease
The French drugmaker is also working on sutimlimab, an antibody for cold agglutinin disease in phase 3 testing, long-acting clotting factor BIVV001 for haemophilia A (phase 2) and gene-editing
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- bluebird bio reveals plans to launch two gene therapies
- AstraZeneca and MSD’s breast cancer drug Lynparza receives EC approval
- Eli Lilly to make bebtelovimab commercially available to US states from August
- Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV
- The patient voice – the value of patient-reported outcomes in HTA
- Biogen and Eisai share latest lecanemab results for the treatment of Alzheimer's disease
- Strategic commitment
- Pfizer set to acquire Global Blood Therapeutics in deal worth $5.4bn
- AstraZeneca and Daiichi Sankyo get FDA approval for breast cancer drug
- NHS England launches hepatitis C screening scheme to reach 2030 elimination goal
- Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer
- Valneva and Pfizer initiate phase 3 Lyme disease vaccine study
- GSK’s ViiV and Medicines Patent Pool agree deal for HIV prevention
- GSK/Merck KGgA cancer drug fails in third trial
- Chiesi Group's Trimbow wins European licence
- Roche shares new positive Ocrevus data for MS patients
- Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection
- Using behavioural psychology to improve patient recruitment
PMHub
11 London
We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...
Latest intelligence
- Strategic commitment
- ...
- KOL Ambassador Program & Podcast Creation: A Customer Story
- ...
- Animation: Living With
- The journey from the patient's perspective...
